Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ameet Sarpatwari, J.D., Ph.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Beall RF, Kesselheim AS, Sarpatwari A. New Drug Formulations and Their Respective Generic Entry Dates. J Manag Care Spec Pharm. 2019 Feb; 25(2):218-224. PMID: 30698097.
    Citations:    Fields:    
  2. Sarpatwari A, Kesselheim AS. Tepid Steps on Drug Pricing. JAMA Intern Med. 2019 Jan 22. PMID: 30667462.
    Citations:    Fields:    
  3. Gopalakrishnan C, Gagne JJ, Sarpatwari A, Dejene SZ, Dutcher SK, Levin R, Franklin JM, Schneeweiss S, Desai RJ. Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clin Pharmacol Ther. 2019 Jan 19. PMID: 30659590.
    Citations:    Fields:    
  4. Sarpatwari A, Gagne JJ, Lu Z, Campbell EG, Carman WJ, Enger CL, Dutcher SK, Jiang W, Kesselheim AS. A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. J Gen Intern Med. 2019 Mar; 34(3):420-428. PMID: 30632102.
    Citations:    Fields:    
  5. Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, Fischer MA, Gagne JJ, Connolly JG. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Saf. 2019 01; 42(1):85-93. PMID: 30066315.
    Citations:    Fields:    
  6. Sarpatwari A, Barenie R, Curfman G, Darrow JJ, Kesselheim AS. The US Biosimilar Market: Stunted Growth and Possible Reforms. Clin Pharmacol Ther. 2019 Jan; 105(1):92-100. PMID: 30415479.
    Citations:    Fields:    
  7. Gagne JJ, Sarpatwari A, Desai RJ. Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products. Clin Pharmacol Ther. 2019 Feb; 105(2):313-315. PMID: 30593655.
    Citations:    Fields:    
  8. Avorn J, Kesselheim A, Sarpatwari A. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20; 379(12):1097-1099. PMID: 30231220.
    Citations:    Fields:    
  9. Lynch HF, Zettler PJ, Sarpatwari A. Promoting Patient Interests in Implementing the Federal Right to Try Act. JAMA. 2018 Sep 04; 320(9):869-870. PMID: 30105394.
    Citations:    Fields:    Translation:Humans
  10. Sarpatwari A, Avorn J, Kesselheim AS. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. JAMA. 2018 06 19; 319(23):2373-2374. PMID: 29800027.
    Citations: 1     Fields:    
  11. Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. Health Aff (Millwood). 2018 05; 37(5):732-737. PMID: 29733729.
    Citations:    Fields:    Translation:Humans
  12. Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly J, Fischer MA, Kesselheim AS, Gagne JJ. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ. 2018 Apr 03; 361:k1180. PMID: 29615391.
    Citations: 3     Fields:    Translation:Humans
  13. Fuse Brown EC, Sarpatwari A. Removing ERISA's Impediment to State Health Reform. N Engl J Med. 2018 Jan 04; 378(1):5-7. PMID: 29298152.
    Citations:    Fields:    
  14. Curfman GD, Beletsky L, Sarpatwari A. Benefits, Limitations, and Value of Abuse-Deterrent Opioids. JAMA Intern Med. 2018 01 01; 178(1):131-132. PMID: 29228102.
    Citations:    Fields:    
  15. Sarpatwari A, Gluck AR, Curfman GD. The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics. JAMA Intern Med. 2018 01 01; 178(1):5-6. PMID: 29131908.
    Citations:    Fields:    
  16. Sarpatwari A, Lee MP, Gagne JJ, Lu Z, Dutcher SK, Jiang W, Campbell EG, Kesselheim AS. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clin Pharmacol Ther. 2018 Jun; 103(6):1093-1099. PMID: 29165800.
    Citations:    Fields:    
  17. Vokinger KN, Kesselheim AS, Avorn J, Sarpatwari A. Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017 11 01; 177(11):1665-1669. PMID: 28975217.
    Citations:    Fields:    Translation:Humans
  18. Sarpatwari A, Choudhry NK. Recalibrating Privacy Protections to Promote Patient Engagement. N Engl J Med. 2017 Oct 19; 377(16):1509-1511. PMID: 29045208.
    Citations:    Fields:    Translation:Humans
  19. Hwang TJ, Kesselheim AS, Sarpatwari A. Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 2017 08 15; 318(7):609-610. PMID: 28692713.
    Citations:    Fields:    
  20. Wang B, Studdert DM, Sarpatwari A, Franklin JM, Landon J, Kesselheim AS. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS One. 2017; 12(4):e0175313. PMID: 28388667.
    Citations:    Fields:    
  21. Sarpatwari A, Gagne JJ, Levidow NL, Kesselheim AS. Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Drug Saf. 2017 02; 40(2):105-108. PMID: 27838823.
    Citations:    Fields:    Translation:Humans
  22. Kesselheim AS, Rome BN, Sarpatwari A, Avorn J. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Aff (Millwood). 2017 02 01; 36(2):362-370. PMID: 28100464.
    Citations:    Fields:    Translation:Humans
  23. Sarpatwari A, Avorn J, Kesselheim AS. Factors Influencing Prescription Drug Costs in the United States-Reply. JAMA. 2016 12 13; 316(22):2431-2432. PMID: 27959994.
    Citations:    Fields:    Translation:Humans
  24. Kesselheim AS, Avorn J, Sarpatwari A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30; 316(8):858-71. PMID: 27552619.
    Citations: 22     Fields:    Translation:Humans
  25. Yeh JS, Sarpatwari A, Kesselheim AS. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. Drug Saf. 2016 08; 39(8):709-14. PMID: 27000800.
    Citations:    Fields:    Translation:Humans
  26. Sarpatwari A, Kesselheim AS. Navigating the Dermatological Drug Cost Curve. JAMA. 2016 Jun 28; 315(24):2724-5. PMID: 27367767.
    Citations:    Fields:    Translation:Humans
  27. Sarpatwari A, Avorn J, Kesselheim AS. State Initiatives to Control Medication Costs--Can Transparency Legislation Help? N Engl J Med. 2016 Jun 16; 374(24):2301-4. PMID: 27305189.
    Citations: 6     Fields:    Translation:Humans
  28. Sarpatwari A, Gagne JJ. Balancing benefits and harms: privacy protection policies. Pharmacoepidemiol Drug Saf. 2016 08; 25(8):969-71. PMID: 27278106.
    Citations:    Fields:    
  29. Sarpatwari A, Kesselheim AS. Efficacy of the Priority Review Voucher Program. JAMA. 2016 Apr 19; 315(15):1660-1. PMID: 27092839.
    Citations:    Fields:    Translation:Humans
  30. Sarpatwari A, Kesselheim AS. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry? PLoS Med. 2016 Feb; 13(2):e1001955. PMID: 26859662; PMCID: PMC4747525.
    Citations:    Fields:    Translation:Humans
  31. Luo J, Sarpatwari A, Kesselheim AS. Regulatory Solutions to the Problem of High Generic Drug Costs. Open Forum Infect Dis. 2015 Dec; 2(4):ofv179. PMID: 26693494; PMCID: PMC4685151.
    Citations: 2     
  32. Kesselheim AS, Maggs LR, Sarpatwari A. Experience With the Priority Review Voucher Program for Drug Development. JAMA. 2015 Oct 27; 314(16):1687-8. PMID: 26414802.
    Citations: 9     Fields:    Translation:Humans
  33. Sarpatwari A, Kesselheim AS. The 21st century cures act: Opportunities and challenges. Clin Pharmacol Ther. 2015 Dec; 98(6):575-7. PMID: 26264909.
    Citations:    Fields:    Translation:HumansPHPublic Health
  34. Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and Permitted Statements about Medications--Loosening the Rules. N Engl J Med. 2015 Sep 03; 373(10):967-73. PMID: 26332553.
    Citations: 4     Fields:    Translation:Humans
  35. Sarpatwari A, Avorn J, Kesselheim AS. Progress and Hurdles for Follow-on Biologics. N Engl J Med. 2015 Jun 18; 372(25):2380-2. PMID: 25946143.
    Citations: 6     Fields:    
  36. Sarpatwari A, Darrow JJ, Kesselheim AS. Expanded access to investigational drugs. N Engl J Med. 2015 04 09; 372(15):1473-4. PMID: 25853762.
    Citations: 1     Fields:    Translation:Humans
  37. Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS. Paying physicians to prescribe generic drugs and follow-on biologics in the United States. PLoS Med. 2015 Mar; 12(3):e1001802. PMID: 25781468; PMCID: PMC4363899.
    Citations: 4     Fields:    Translation:Humans
  38. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015 Jan 15; 372(3):279-86. PMID: 25587952.
    Citations: 14     Fields:    Translation:Humans
  39. Sarpatwari A, Franklin JM, Avorn J, Seeger JD, Landon JE, Kesselheim AS. Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia. Clin Pharmacol Ther. 2015 Feb; 97(2):186-93. PMID: 25670524.
    Citations: 1     Fields:    Translation:Humans
  40. Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss S. Ensuring patient privacy in data sharing for postapproval research. N Engl J Med. 2014 Oct 23; 371(17):1644-9. PMID: 25337755.
    Citations: 5     Fields:    Translation:Humans
  41. Sarpatwari A, Avorn J, Kesselheim AS. Using a drug-safety tool to prevent competition. N Engl J Med. 2014 Apr 17; 370(16):1476-8. PMID: 24738666.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  42. Anzures-Cabrera J, Sarpatwari A, Higgins JP. Expressing findings from meta-analyses of continuous outcomes in terms of risks. Stat Med. 2011 Nov 10; 30(25):2967-85. PMID: 21826697.
    Citations: 11     Fields:    Translation:Humans
  43. Sarpatwari A, Bussel JB, Ahmed M, Erqou S, Semple JW, Newland AC, Bennett D, Pharoah P, Provan D. Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology. 2011 Jul; 16(4):243-8. PMID: 21756542.
    Citations: 3     Fields:    Translation:Humans
  44. Sarpatwari A, Provan D, Erqou S, Sobnack R, David Tai FW, Newland AC. Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol. 2010 Dec; 151(5):477-87. PMID: 20950403.
    Citations: 11     Fields:    Translation:HumansCells
  45. Sarpatwari A, Watson S, Erqou S, Anderson H, Grainger J, Higgins JP, Newland AC. Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). Br J Haematol. 2010 Oct; 151(2):189-91. PMID: 20666773.
    Citations:    Fields:    Translation:Humans
  46. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010 Jul; 95(7):1167-75. PMID: 20145266; PMCID: PMC2895042.
    Citations: 18     Fields:    Translation:Humans
  47. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009 Feb 05; 113(6):1231-40. PMID: 18945961.
    Citations: 48     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu. SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Sarpatwari's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (174)
Explore
_
Co-Authors (16)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.